-
Tytuł:
-
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.
-
Autorzy:
-
About F; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Paris, France.; Paris Descartes University, Imagine Institute, Paris, France.
Oudot-Mellakh T; Laboratory of Immunity and Infection, Centre d'Immunologie et des Maladies Infectieuses de Paris (CIMI), INSERM U1135, Groupe Hospitalier Pitié Salpétrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.; Plateforme Génomique Inserm-ANRS, Groupe Hospitalier Pitié Salpétrière, AP-HP, UPMC Université Paris 6, Paris, France.
Niay J; Laboratory of Immunity and Infection, Centre d'Immunologie et des Maladies Infectieuses de Paris (CIMI), INSERM U1135, Groupe Hospitalier Pitié Salpétrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.; Plateforme Génomique Inserm-ANRS, Groupe Hospitalier Pitié Salpétrière, AP-HP, UPMC Université Paris 6, Paris, France.
Rabiéga P; Sorbonne Universités, UPMC Université Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.
Pedergnana V; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Paris, France.; Paris Descartes University, Imagine Institute, Paris, France.; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
Duffy D; Centre for Human Immunology, Department of Immunology, Institut Pasteur, Paris, France.; The Laboratory of Dendritic Cell Biology, Department of Immunology, Institut Pasteur, INSERM U818, Paris, France.
Sultanik P; Département d'Hépatologie, Hôpital Cochin, AP-HP, Université Paris Descartes, Paris, France.; INSERM UMS20, Institut Pasteur, Paris, France.
Cagnot C; Unit for Basic and Clinical research on Viral Hepatitis, Inserm-ANRS (France REcherche Nord & sud Sida-HIV Hépatites-FRENSH), Paris, France.
Carrat F; Sorbonne Universités, UPMC Université Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.; Service de Santé Publique, Hôpital Saint Antoine, AP-HP, Paris, France.
Marcellin P; Service d'Hépatologie, Hôpital Beaujon, Clichy, France.
Zoulim F; Centre de recherche en cancérologie de Lyon (CRCL), INSERM UMR I 1052/CNRS 5286, Lyon cedex 03, France.; Université Claude-Bernard Lyon 1, Villeurbanne, France.; Hospices civils de Lyon, Hôpital de la Croix-Rousse, service d'hépatologie et de gastroentérologie, Lyon, France.
Larrey D; CHU St Eloi Hospital, Liver Unit, Montpellier, France.
Hézode C; Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, AP-HP, Université Paris-Est Créteil (UPEC), Créteil, France.; Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, UPEC, Créteil, France.
Fontaine H; Département d'Hépatologie, Hôpital Cochin, AP-HP, Université Paris Descartes, Paris, France.; INSERM UMS20, Institut Pasteur, Paris, France.
Bronowicki JP; Department of Hepatogastroenterology, INSERM U954, CHU de Nancy, Université de Lorraine, Vandoeuvre-Lès-Nancy, France.
Pol S; Département d'Hépatologie, Hôpital Cochin, AP-HP, Université Paris Descartes, Paris, France.; INSERM UMS20, Institut Pasteur, Paris, France.
Albert ML; Centre for Human Immunology, Department of Immunology, Institut Pasteur, Paris, France.; The Laboratory of Dendritic Cell Biology, Department of Immunology, Institut Pasteur, INSERM U818, Paris, France.; INSERM UMS20, Institut Pasteur, Paris, France.
Theodorou I; Laboratory of Immunity and Infection, Centre d'Immunologie et des Maladies Infectieuses de Paris (CIMI), INSERM U1135, Groupe Hospitalier Pitié Salpétrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.; Plateforme Génomique Inserm-ANRS, Groupe Hospitalier Pitié Salpétrière, AP-HP, UPMC Université Paris 6, Paris, France.
Cobat A; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Paris, France.; Paris Descartes University, Imagine Institute, Paris, France.
Abel L; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Paris, France.; Paris Descartes University, Imagine Institute, Paris, France.; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, United States of America.
-
Corporate Authors:
-
ANRS CO20-CUPIC study group
-
Źródło:
-
PloS one [PLoS One] 2015 Dec 15; Vol. 10 (12), pp. e0145105. Date of Electronic Publication: 2015 Dec 15 (Print Publication: 2015).
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: San Francisco, CA : Public Library of Science
-
MeSH Terms:
-
Hepatitis C, Chronic/*genetics
Interleukins/*genetics
Liver Cirrhosis/*complications
Oligopeptides/*therapeutic use
Polymorphism, Single Nucleotide/*genetics
Proline/*analogs & derivatives
Pyrophosphatases/*genetics
beta 2-Glycoprotein I/*genetics
Anemia/complications ; Drug Therapy, Combination ; Hemoglobins/metabolism ; Hepacivirus/physiology ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/virology ; Humans ; Interferons ; Liver Cirrhosis/drug therapy ; Liver Cirrhosis/genetics ; Liver Cirrhosis/virology ; Oligopeptides/adverse effects ; Proline/adverse effects ; Proline/therapeutic use ; Treatment Outcome
-
References:
-
Annu Rev Genomics Hum Genet. 2013;14:215-43. (PMID: 23724903)
N Engl J Med. 2014 Apr 24;370(17):1604-14. (PMID: 24720679)
Hum Genet. 1999 Jul-Aug;105(1-2):63-71. (PMID: 10480357)
Eur J Gastroenterol Hepatol. 2012 Aug;24(8):890-6. (PMID: 22584257)
Clin Chem. 2006 Feb;52(2):240-7. (PMID: 16384889)
J Hepatol. 2013 Apr;58(4):669-75. (PMID: 23195617)
Eur J Biochem. 2003 Jan;270(2):230-8. (PMID: 12605674)
J Hepatol. 2013 Sep;59(3):434-41. (PMID: 23669289)
Atherosclerosis. 1994 Sep 30;110(1):45-51. (PMID: 7857369)
J Infect Dis. 2011 Jul 1;204(1):84-93. (PMID: 21628662)
Lancet. 2001 Sep 22;358(9286):958-65. (PMID: 11583749)
Hepatol Res. 2014 Dec;44(14):E386-96. (PMID: 24606109)
J Gastroenterol Hepatol. 2014 Jan;29(1):144-50. (PMID: 24117654)
PLoS One. 2014;9(4):e95881. (PMID: 24760000)
Gastroenterology. 2012 Sep;143(3):608-18.e1-5. (PMID: 22626609)
J Lipid Res. 2008 Dec;49(12):2648-56. (PMID: 18676959)
Gastroenterology. 2014 Jul;147(1):132-142.e4. (PMID: 24704719)
Nature. 2010 Mar 18;464(7287):405-8. (PMID: 20173735)
Gastroenterology. 2010 Oct;139(4):1181-9. (PMID: 20547162)
Hepatology. 2011 Feb;53(2):415-21. (PMID: 21246582)
N Engl J Med. 2011 Mar 31;364(13):1207-17. (PMID: 21449784)
J Viral Hepat. 2012 Oct;19(10):677-84. (PMID: 22967098)
J Thromb Haemost. 2013 Mar;11(3):521-8. (PMID: 23279374)
World J Gastroenterol. 2013 Mar 7;19(9):1387-95. (PMID: 23538996)
J Hepatol. 2013 May;58(5):883-9. (PMID: 23321318)
N Engl J Med. 2011 Jun 23;364(25):2417-28. (PMID: 21696308)
J Rheumatol. 2009 Feb;36(2):315-22. (PMID: 19132787)
Aliment Pharmacol Ther. 2015 Apr;41(7):671-85. (PMID: 25627020)
N Engl J Med. 2002 Sep 26;347(13):975-82. (PMID: 12324553)
J Clin Microbiol. 2013 Sep;51(9):2862-8. (PMID: 23784126)
J Viral Hepat. 2013 Dec;20(12):858-66. (PMID: 24304455)
Nat Genet. 2013 Feb;45(2):164-71. (PMID: 23291588)
Nature. 2009 Sep 17;461(7262):399-401. (PMID: 19684573)
J Hepatol. 2014 Nov;61(1 Suppl):S45-57. (PMID: 25086286)
Liver Int. 2015 Jul;35(7):1833-44. (PMID: 25556540)
-
Contributed Indexing:
-
Investigator: C Hézode; H Fontaine; T Poynard; V Canva; P Cacoub; D Samuel; P Marcellin; L Alric; V De Lédinghen; M Bourlière; JP Zarski; JJ Raabe; S Métivier; L Serfaty; G Riachi; A Abergel; V Loustaud-Ratti; A Tran; X Causse; D Guyader; PH Bernard; P Attali; V Di-Martino; P Calès; V Grando-Lemaire; I Rosa; D Botta-Friedland; T Dao; D Lucidarme; P Hillon; C Feray; T Fontanges; JD Grange; G Gatineau-Sailliant; E Poncin; JP Arpurt; Y Bacq; P Delasalle; D Ouzan; JB Nousbaum; C Sylvain; D Ribard; P Renard; C Lascoux-Combe; S de Montigny-Lenhardt; C Pilette; J Denis; T Allègre; M Schnee; G Franck; JM Combis; P Bedossa; JM Pawlotsky; M L'Henaff; M Sizorn; V Petrov-Sanchez; O Chazouillères; J Dubuisson; F Negro; GP Pageaux; V Paradis; B Spire; AM Taburet; JC Trinchet; Y Yazdanpanah; C Dorival-Mouly; C Dufour; C Fréhaut; A Lesel; N Zahraa; M Pirot; Y Barthe; F Chau
-
Substance Nomenclature:
-
0 (Hemoglobins)
0 (interferon-lambda, human)
0 (Interleukins)
0 (Oligopeptides)
0 (beta 2-Glycoprotein I)
655M5O3W0U (telaprevir)
89BT58KELH (N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide)
9008-11-1 (Interferons)
9DLQ4CIU6V (Proline)
EC 3.6.1.- (Pyrophosphatases)
EC 3.6.1.9 (ITPA protein, human)
-
Entry Date(s):
-
Date Created: 20151217 Date Completed: 20160627 Latest Revision: 20231213
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC4682920
-
DOI:
-
10.1371/journal.pone.0145105
-
PMID:
-
26670100
-
Background: Human genetic factors influence the outcome of pegylated interferon and ribavirin hepatitis C therapy. We explored the role of IL28B, APOH and ITPA SNPs on the outcomes of triple therapy including telaprevir or boceprevir in patients with compensated cirrhosis chronically infected with HCV-1.
Patients and Methods: A total of 256 HCV-1 Caucasian treatment-experienced patients with compensated cirrhosis from the ANRS CO20-CUPIC cohort were genotyped for a total of 10 candidate SNPs in IL28B (rs12979860 and rs368234815), APOH (rs8178822, rs12944940, rs10048158, rs52797880, rs1801689 and rs1801690) and ITPA (rs1127354 and rs7270101). We tested the association of IL28B and APOH SNPs with sustained virological response and of ITPA SNPs with anemia related phenotypes by means of logistic regression assuming an additive genetic model.
Results: None of the six APOH SNPs were associated with sustained virological response. The favorable alleles of the IL28B SNPs rs12979860 and rs368234815 were associated with sustained virological response (rs12979860: OR = 2.35[1.50-3.70], P = 2x10(-4)). Refined analysis showed that the effect of IL28B SNPs on sustained virological response was restricted to prior PegIFN/RBV relapse (OR = 3.80[1.82-8.92], P = 8x10(-4)). We also confirmed the association between ITPA low activity alleles and protection against early hemoglobin decline in triple therapy (P = 2x10(-5)).
Conclusion: Our results suggest that the screening of rs12979860 may remain interesting for decision making in prior relapse HCV-1 Caucasian patients with compensated cirrhosis eligible for a telaprevir- or boceprevir-based therapy.
